GLUE
Monte Rosa Therapeutics, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth +12.5% ·
share flow -6.0% ·
net new positions +11.1%
— formula
Ownership fragmentation — more holders, smaller aggregate stake
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 77 | -4 | 40.74M | $985.15M | +4 | −8 |
| Q1 2026 | 84 | +11 | 37.29M | $613.27M | +14 | −3 |
| Q4 2025 | 73 | -1 | 26.21M | $411.01M | +1 | −2 |
| Q3 2025 | 18 | +2 | 20.02M | $148.32M | +2 | — |
| Q2 2025 | 13 | +1 | 20.51M | $92.50M | +1 | — |
| Q1 2025 | 9 | -3 | 9.96M | $46.20M | +1 | −4 |
| Q4 2024 | 12 | +2 | 11.82M | $82.01M | +2 | — |
| Q3 2024 | 9 | +2 | 9.48M | $50.23M | +2 | — |
| Q2 2024 | 7 | — | 8.29M | $30.99M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | T. Rowe Price ✦ | 4.64M | -26.7% | $34.36M | 0.0% | ▼ Trim | 6 | SEC ↗ ×2 |
| 2 | BlackRock ✦ (passive) | 3.82M | -0.8% | $28.27M | 0.0% | ▼ Trim | 2 | SEC ↗ ×8 |
| 3 | The Vanguard Group ✦ (passive) | 2.99M | -4.8% | $22.15M | 0.0% | ▼ Trim | 2 | SEC ↗ ×3 |
| 4 | Fidelity (FMR) ✦ | 2.81M | +22.9% | $20.84M | 0.0% | ▲ Add | 2 | SEC ↗ ×3 |
| 5 | Geode Capital Management ✦ (passive) | 1.15M | +2.4% | $8.53M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 6 | Marshall Wace ✦ | 902.83K | +102.4% | $6.69M | 0.0% | ▲ Add | 5 | SEC ↗ ×3 |
| 7 | State Street Global Advisors ✦ (passive) | 846.77K | +1.8% | $6.27M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 8 | AQR Capital Management ✦ | 717.26K | -44.1% | $5.31M | 0.0% | ▼ Trim | 3 | SEC ↗ ×5 |
| 9 | Morgan Stanley ✦ | 645.20K | — | $4.78M | 0.0% | n/c | 1 | SEC ↗ ×7 |
| 10 | Millennium Management ✦ | 444.94K | +588.4% | $3.30M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 11 | Renaissance Technologies ✦ | 395.73K | -35.7% | $2.93M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 12 | Two Sigma Investments ✦ | 161.48K | -32.7% | $1.20M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 13 | Wellington Management ✦ | 158.52K | -29.5% | $1.17M | 0.0% | ▼ Trim | 6 | SEC ↗ ×3 |
| 14 | Goldman Sachs Group ✦ | 101.14K | — | $749,477 | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 15 | Point72 Asset Management ✦ | 90.42K | New | $670,005 | 0.0% | New | 1 | SEC ↗ |
| 16 | Citadel Advisors ✦ | 51.01K | -34.5% | $377,976 | 0.0% | ▼ Trim | 2 | SEC ↗ ×2 |
| 17 | D. E. Shaw & Co. ✦ | 50.21K | New | $372,078 | 0.0% | New | 1 | SEC ↗ |
| 18 | JPMorgan Chase ✦ | 45.88K | — | $339,956 | 0.0% | n/c | 1 | SEC ↗ ×6 |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| Point72 Asset Management | $670,005 | 0.0% |
| D. E. Shaw & Co. | $372,078 | 0.0% |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 188 holders, 86.88M shares, $1.31B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 13 sh · $137
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology
7.9% of class · View original SEC filing ↗